Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Mounjaro Clear all

Conditions: Obesity
Interventions: Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 35 Years to 60 Years
Enrollment: 30 participants
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Interventions: Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone; Procedure · Radiation · Drug
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Obesity and Obesity-related Medical Conditions
Interventions: Mounjaro, Sleeve Gastrectomy; Drug · Procedure
Lead sponsor: Nicholas Skertich; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity, Overweight and Obesity, Overweight
Interventions: Tirzepatide; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: MASLD, Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Type 2 Diabetes (Adult Onset)
Interventions: Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Obesity & Overweight, Diabetes (DM)
Interventions: Glucagon-Like Peptide-1 Agonist (GLP-1); Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus, Type 2, Obesity, Gastroparesis
Interventions: GLP-1 medication; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Not listed
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Weston, Florida • Cleveland, Ohio

Conditions: Obesity
Interventions: Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide, Naltrexone-Bupropion, Phentermine-Topiramate, Semaglutide (Wegovy®); Other · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 25 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sarcoma,Soft Tissue
Interventions: Tirzepatide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity and Obesity-related Medical Conditions
Interventions: Bariatric Surgery, Semaglutide, Tirzepatide; Procedure · Drug
Lead sponsor: Ali Aminian; Other
Eligibility: 18 Years to 70 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type II Diabetes, Atherosclerosis
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Matthew J. Budoff; Other
Eligibility: 40 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Torrance, California

Conditions: Methamphetamine Use Disorder
Interventions: Tirzepatide, Placebo (saline); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Tulsa, Oklahoma + 1 more

Conditions: Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions: Tirzepatide; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbia, Maryland

Conditions: Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Interventions: Tirzepatide; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more

Conditions: Severe Obesity, Obesity, BMI Greater Than 30
Interventions: Tirzepatide, Standard of Care post-gastric bypass; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 25 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obesity, Methamphetamine Use Disorder
Interventions: Tirzepatide; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity and Obesity-related Medical Conditions, Bariatric Surgery
Interventions: tirzepatide, Standard of Care; Drug · Behavioral
Lead sponsor: Marlene Starr; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Obesity and Overweight
Interventions: NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide; Drug
Lead sponsor: Biomed Industries, Inc.; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 5 more

Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions: Metabolic surgery, Incretin-Based Therapy; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more

Conditions: Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol Use Disorder (AUD)
Interventions: Tirzepatide, Saline Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Jamaica Plain, Massachusetts

Conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Lipodystrophy, Partial
Interventions: Tirzepatide, Usual care medications; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Anti-obesity Pharmacotherapy and Inflammation

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

Tirzepatide for Treatment of CCCA

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

Tirzepatide for Obesity and Meth Use Disorder

2024 Tirzepatide-Bariatric Surgery

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Fibrosis Lessens After Metabolic Surgery

Incretin Therapies in Obesity-related HFpEF

Study of Tirzepatide for Recovery and Alcohol Use Management

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024